tesaro horlick transact viiv investor event
updat gsk model incorpor expect dilut
tesaro reflect increment invest expect gsk put behind
zejula npv tesaro asset suggest gsk pay
effect group broader oncolog capabilities/goodwil
made minim chang viiv expect compound-annual-growth-rate sale
see deal wholli line group strategi build
oncolog franchis ad short-term asset regulatory/
commerci expertis howev goe small way fix lack
 pipelin would move group bottom quartil
posit term replac power shown octob
pharmavalu report howev remain confid cash flow
gener group continu pay dividend absenc
see final launch us gener advair slow viiv
franchis continu see long term price pressur partial
off-set strong vaccin consum franchis also bring
extern invest bolster pipelin would expect dispos
older tail asset bolster balanc sheet see stock remain
catalyst risk us gener advair time remain overhang
weaken viiv growth posit news flow could come data
trelegi asthma bcma oncolog next hiv doublet launch
valuat gsk trade pe premium eu
sector npv/ev premium eu discount
global major
valuat metric
price-to-earnings rel local market
price month
price rel chart measur perform
ftse share close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
glaxosmithklin plc gsk global healthcar group
engag creation discoveri develop manufactur
market pharmaceut product includ vaccin
medicin health-rel consum product
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
analysi show impact pipelin success
stronger forecast growth respiratori franchis
uncertainti impact us advair gener viiv
uncertainti level competit new drug gener
grey analysi show impact full pipelin failur
weaker forecast growth respiratori franchis
uncertainti impact us advair gener viiv
uncertainti level competit new drug gener
price rel chart measur perform ftse share
close
spot exchang rate
decemb gsk announc divestitur horlick
consum healthcar nutrit brand unilev line previously-
announc strateg review busi total gross consider
transact net proce tax fee hedg estim
deal larg structur merger gsk indian busi gsk
consum healthcar ltd hindustan unilev limit hul publicli list
compani nation bombay stock exchang follow transact
gsk stake hul three key element deal
stake hul valu
cash gsk bangladesh
cash right territori
gsk realiz major valu transact sell
sharehold hul tranch onward
deal expect close understand
horlick gsk consum india remain fulli consolid gsk
expect may book asset held dispos balanc sheet
follow transact hul becom distributor gsk consum over-the-counter
brand india line current arrang gsk consum
healthcar india distributor gsk over-the-counter brand india assum
chang term distribut agreement remaind portfolio
asset dispos contribut revenu ebit margin
low percent
date asset contribut revenu ebit margin low
gsk own gsk consum healthcar ltd book minor pay away
 remaind estim minor charg post-tax
previous assum divestitur horlick follow gsk comment
strateg review product
updat assumpt actual valu transact
assum cash gsk bangladesh intern product right
book end assum tax payabl proce
assum valu gsk stake hul realis year end
tax
decemb gsk also announc agreement acquir tesaro us
commerci stage biotech compani focus oncolog
deal expect complet
gsk agre pay per share total cash repres
premium tesaro day volum weight averag price
tesaro lead asset zejula niraparib ovarian cancer zejula parp inhibitor
current approv ovarian cancer comer highli competit
market includ clovi rubraca azn/mrk lynparza pfizer talzenna also
approv brca mutant breast cancer
zejula also develop mainten ovarian prima trial patient
homolog repair defici hrd neg repres
mainten patient studi expect readout contrast
azn/mrk recent readout restrict brca mutant mainten
popul approxim one third size figur
prima studi also includ patient normal hrd statu mainten
ovarian set hrd neg subgroup statist signific alpha
recycl all-com patient popul would increas treatment
potenti doubl hrd neg subgroup see significantli
zejula develop indic intern io combin zejula also
develop indic breast pancreat prostat small-cel lung
cancer monotherapi combin antibodi addit tesaro
multipl
dostarlimab believ deal bring establish
oncolog team boston
pipelin
compani state assum complet acquisit
neg adj ep mid high singl digit percentag
reduc time due associ commerci invest gsk would
expect acquisit accret adjust ep
guidanc unchang adj ep group outlook also
confirm expect adj ep growth bottom end
mid high singl digit percentag compound-annual-growth-rate rang
figur set cs revenu assumpt zejula ovarian
mainten set assum probability-adjust sale
assum combin royalti pay-away astrazeneca
payment relat cross-licens parp clinic data ip two royalti
stream disclos mid-singl digit low singl digit respect
line manag comment assum gsk step invest
tsro platform significantli consensu forecast previous assum loss
break even note gsk still target
posit earn contribut tsro invest aggress
 commerci near term
key takeaway
gsk confid breadth hiv portfolio overal growth
us still earli uptak curv two drug regimen gsk
expect growth come product driven dolutegravir /lamivudin
broad patient popul togeth enhanc messag use paid
speaker gsk except sustain overal us share continu see price rise
innov
ex-u growth share improv patient penetr strong
growth come matur market eu japan australia lead
develop market brazil russia china patient opportun larg
overal gsk expect growth hiv portfolio cs publish yr viiv compound-annual-growth-rate sale
skeptic audienc sustain price
seen evid enhanc rebat yet note pharmafood
thought rebat highlight on-going low level hiv drug rebat figur
current gross net price per day tripl doublet therapi
figur gsk confid chang allow step edit protect part
plan would big impact senior hiv like treatment
mani year treatment nave like amen easi shift
altern therapi
prostat
charl martineau univers toronto chang group forecast
figur chang forecast
pharma
pharma
pharma
chang lc ep growth
charl martineau univers toronto figur use adjust free cash flow time
free adj
 adj tax
figur use adjust free cash flow next year
 adj tax
estim gsk free cash flow support sustain dividend allow
modest de-lever compani would expect partial
off-set cash flow dispos gsk appear less activ peer
dispos tail asset
gsk premium/ discount eu
gsk premium/ discount global
profit tax underli gsk cs
profit tax underli gsk
profit tax report
average share
ep gsk fd
increment ep delay us gener advair
compani mention price
